


New Treatments for Geographic Atrophy secondary to Dry Macular degeneration.

In 2023, the FDA has approved two drugs for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD):

Syfovre (pegcetacoplan injection): Approved by the FDA in February 2023, Syfovre became the first-ever treatment to slow the progression of vision loss from geographic atrophy, an advanced form of dry age-related macular degeneration and a leading cause of blindness. It works by modifying the function of the C3 component of the complement system, which is involved in the immune response and has been implicated in the development of GA.



www.syfovre.com

Izervay (avacincaptad pegol intravitreal solution): This drug received FDA approval in August 2023. Izervay is a complement C5 inhibitor and has been shown to slow the progression of geographic atrophy by targeting excessive activation of the complement system. Clinical trials demonstrated that Izervay could reduce the rate of GA lesion growth by about 35% by blocking excess production of the C5 protein. Izervay is administered as an injection in the eye once a month for up to 12 months.



www.izervay.com

These approvals represent significant advancements in the treatment options available for geographic atrophy, offering hope to millions of people worldwide who are at risk of irreversible blindness from this condition.

EU and UK approval is expected in 2024. It will require to be assessed by NICE before it is available under the NHS in the UK. Though will be available privately once it is licensed.

Nicholas Lee 2023

User

which nhs hospital does Mr Andrew Luff in the south of eng